These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347 [TBL] [Abstract][Full Text] [Related]
9. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. Hsu JH; Yang SN; Chen HL; Tseng HI; Dai ZK; Wu JR J Pediatr; 2010 Jul; 157(1):79-84. PubMed ID: 20227723 [TBL] [Abstract][Full Text] [Related]
10. Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants. Rodriguez-Blanco S; Oulego-Erroz I; Gautreaux-Minaya S; Perez-Muñuzuri A; Couce-Pico ML J Perinatol; 2018 Jul; 38(7):881-888. PubMed ID: 29785059 [TBL] [Abstract][Full Text] [Related]
11. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants. Nuntnarumit P; Chongkongkiat P; Khositseth A Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304 [TBL] [Abstract][Full Text] [Related]
12. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. Nuntnarumit P; Khositseth A; Thanomsingh P J Perinatol; 2009 Feb; 29(2):137-42. PubMed ID: 19020527 [TBL] [Abstract][Full Text] [Related]
13. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Kulkarni M; Gokulakrishnan G; Price J; Fernandes CJ; Leeflang M; Pammi M Pediatrics; 2015 Feb; 135(2):e510-25. PubMed ID: 25601976 [TBL] [Abstract][Full Text] [Related]
14. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Puddy VF; Amirmansour C; Williams AF; Singer DR Clin Sci (Lond); 2002 Jul; 103(1):75-7. PubMed ID: 12095406 [TBL] [Abstract][Full Text] [Related]
15. Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus. Oh SH; Lee BS; Jung E; Oh MY; Do HJ; Kim EA; Kim KS Sci Rep; 2020 Mar; 10(1):4430. PubMed ID: 32157119 [TBL] [Abstract][Full Text] [Related]
16. [Usefulness of brain natriuretic propeptide in the diagnosis and management of patent ductus arteriosus]. Montaner Ramón A; Galve Pradel Z; Fernández Espuelas C; Jiménez Montañés L; Samper Villagrasa MP; Rite Gracia S An Pediatr (Barc); 2017 Jun; 86(6):321-328. PubMed ID: 26936584 [TBL] [Abstract][Full Text] [Related]
17. Cerebral oxygenation during different treatment strategies for a patent ductus arteriosus. Chock VY; Ramamoorthy C; Van Meurs KP Neonatology; 2011; 100(3):233-40. PubMed ID: 21701212 [TBL] [Abstract][Full Text] [Related]
18. B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants. König K; Guy KJ; Drew SM; Barfield CP Acta Paediatr; 2015 Apr; 104(4):e139-42. PubMed ID: 25488470 [TBL] [Abstract][Full Text] [Related]
19. Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. Weisz DE; McNamara PJ; El-Khuffash A Early Hum Dev; 2017 Feb; 105():41-47. PubMed ID: 27998626 [TBL] [Abstract][Full Text] [Related]